Novartis has agreed to help manufacture a COVID-19 vaccine jointly developed by Pfizer and BioNTech to support the vaccine supply chain, the Swiss drugmaker. announced January 29th.
Using its manufacturing facility in Stein, Switzerland, Novartis will fill the vial with bulk messenger RNA (the active ingredient of the vaccine) and ship it to BioNTech. The amount has not been disclosed, as the deal reached a final agreement.
Novartis plans to start production in the second quarter of 2021, with initial deliveries slated for the third quarter.
Steffen Lang, Novartis’ head of technical operations, said in a news release that the drugmaker is committed to using its manufacturing capabilities to help end the pandemic and expects this agreement “to be the first of a number of such agreements.”
The announcement comes two days after French pharmaceutical giant Sanofi announced his plans to produce more than 125 million doses of the vaccine developed by Pfizer and BioNTech.
More articles on pharmacy:
Executives from the Cleveland Clinic, Baystate Health share the challenges facing their vaccine program
Antibody drug Eli Lilly COVID-19 reduces hospitalization, risk of death, trials
J&J says its COVID-19 vaccine is 66% effective
© Copyright ASC COMMUNICATIONS 2021. Interested in CONNECTING or REPRINTING this content? Check out our policies with clicking here.